Tempus AI, Inc. is trading 5.2% up now at $53.08 following a positive analyst update and the introduction of a new oncology product.
- Needham today reiterated its Buy rating and $75 price target on the stock, reinforcing optimism around the company’s growth prospects.
- Investors are reacting to the upcoming launch of the xH whole-genome sequencing assay, which aims to identify approximately 40% more actionable cancer targets in hematologic malignancies.